Schroder Investment Management Group raised its holdings in Biogen Inc. (NASDAQ:BIIB) by 38.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 305,970 shares of the biotechnology company’s stock after purchasing an additional 84,981 shares during the quarter. Schroder Investment Management Group owned about 0.14% of Biogen worth $83,187,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Bienville Capital Management LLC increased its stake in Biogen by 2.2% in the second quarter. Bienville Capital Management LLC now owns 880 shares of the biotechnology company’s stock valued at $239,000 after purchasing an additional 19 shares during the period. Provident Investment Management Inc. increased its stake in Biogen by 1.6% in the second quarter. Provident Investment Management Inc. now owns 66,356 shares of the biotechnology company’s stock valued at $18,006,000 after purchasing an additional 1,044 shares during the period. LSV Asset Management increased its stake in Biogen by 1,196.3% in the second quarter. LSV Asset Management now owns 445,539 shares of the biotechnology company’s stock valued at $120,901,000 after purchasing an additional 411,170 shares during the period. Calamos Advisors LLC increased its stake in Biogen by 2.5% in the second quarter. Calamos Advisors LLC now owns 28,805 shares of the biotechnology company’s stock valued at $7,817,000 after purchasing an additional 713 shares during the period. Finally, Meiji Yasuda Life Insurance Co increased its stake in Biogen by 23.4% in the second quarter. Meiji Yasuda Life Insurance Co now owns 6,866 shares of the biotechnology company’s stock valued at $1,863,000 after purchasing an additional 1,300 shares during the period. Institutional investors own 87.65% of the company’s stock.

Shares of Biogen Inc. (NASDAQ:BIIB) opened at 321.26 on Monday. Biogen Inc. has a 52-week low of $244.28 and a 52-week high of $330.00. The firm has a market cap of $67.92 billion, a price-to-earnings ratio of 21.08 and a beta of 0.77. The stock has a 50 day moving average of $298.79 and a 200 day moving average of $278.33.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, beating the Zacks’ consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter last year, the firm posted $5.21 earnings per share. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities analysts predict that Biogen Inc. will post $21.48 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Schroder Investment Management Group Acquires 84,981 Shares of Biogen Inc. (BIIB)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/18/schroder-investment-management-group-acquires-84981-shares-of-biogen-inc-biib.html.

In other news, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total value of $2,211,030.00. Following the sale, the executive vice president now owns 27,232 shares in the company, valued at $7,761,120. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the completion of the sale, the executive vice president now owns 22,258 shares in the company, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.

Several analysts have recently weighed in on BIIB shares. Vetr raised shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 target price on the stock in a report on Tuesday, June 27th. Deutsche Bank AG started coverage on shares of Biogen in a report on Friday, June 23rd. They issued a “buy” rating and a $315.00 target price on the stock. Robert W. Baird reaffirmed a “hold” rating and issued a $290.00 target price on shares of Biogen in a report on Friday, August 25th. Credit Suisse Group set a $300.00 target price on shares of Biogen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, BMO Capital Markets lifted their target price on shares of Biogen from $328.00 to $377.00 and gave the company a “market perform” rating in a report on Wednesday, September 13th. Thirteen analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Biogen has an average rating of “Buy” and an average target price of $331.53.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.